• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Adrian Hernandez Highlights the Use of Real-World Evidence and Current Barriers

Video

In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.

This page contains sponsored advertising.

In some ways, the United States is progressive in its use of real-world evidence, but there are still areas where other countries do a better job of incorporating such evidence into the health system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine.

Transcript

What are the barriers that prevent the use of real-world evidence in meaningful ways?

There are a few. One is cultural. Just getting used to the concept of taking advantage of data every day that is being generated as part of healthcare and, also, someone’s life journey. The second thing is actually around quality. So, how do we understand what it means? What does the quality of the data implicate in terms of the certainty or uncertainty about the results?

And, then, finally, how do we make sure that we’re actually getting the right answers? So, certainly, there are methodological issues in terms of observational studies. There are also methodological issues in terms of randomized trials. So, how do we get closer to the truth? And combining those 3 efforts is really important for real-world evidence.

How does the United States’ use of real-world evidence compare with how it is used in other countries?

In some ways, it’s very progressive in terms of people actually making decisions. In terms of health decisions. So, healthcare systems are doing this every day. In some cases, it’s being used to inform what regulators have to decide on in terms of either expanding an indication or actually a new indication.

In the other places, however, it’s being incorporated more in the health system, and actually how that actually influences what they do for population health management. So, certain countries are actually very focused in terms of how they’re going to improve the trajectory for health over a 3- or 5-year period. So, they recognize the need for that is actually incorporating real-world evidence to drive outcomes and better health.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.